News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

STD Med, Inc. Med Continues To Grow


5/3/2006 1:29:14 PM

STOUGHTON, Mass., May 3 /PRNewswire/ -- STD Med, Inc. a developer and manufacturer of medical devices based in Stoughton, Massachusetts, announced the buy-back of the minority shareholder interest held by James Lousararian for approximately the past six years and a change to its board of directors, which included the resignation of James Lousararian.

"The family is very pleased to have the Company returned to its prior ownership structure and is looking forward to another fifty years of innovation," said Steven Tallarida, president of STD Med. The Company, founded by Primo Tallarida in 1953 inside the family chicken coupe, has experienced extraordinary growth under the ownership and direction of sons Steven and Jon Tallarida and its senior management.

In less than ten years, STD Med has introduced four new medical device start-up companies.

* Angiolink Corp., a developer of femoral artery closure technology, utilizing a novel staple, was sold to Medtronic, Inc. in November 2004. * Arthrosurface, Inc. based in Franklin, MA, specializes in the repair of early stage cartilage damage. Arthrosurface has developed and received FDA clearance for several of the orthopedic industry's first true "mini" total joint systems. The company's HemiCap System is receiving great clinical acceptance. * Spirus Medical Inc. has developed a revolutionary Endoluminal Advancement System (EAS(TM)) for GI Endoscopy that represents a significant breakthrough by enabling gastroenterologists to perform flexible endoscopy procedures more efficiently. In addition, Spirus is developing other devices incorporating their same proprietary helix technology for use in urological and gynecological procedures. * CardioSolutions is currently in incubation at STD Med. CardioSolutions is developing a minimally invasive heart repair system to treat patients with mitral valve prolapse. Their Mitral Spacer (patent pending) is percutaneously placed into the heart. The company believes this device will create a major breakthrough in mitral valve repair.

Andrea Patisteas, Vice President of Sales & Marketing at STD Med said, "It is our intention to incubate one or more innovative technologies every fourteen to eighteen months."

For further information, contact STD Med, Inc. P.O. Box 420, Stoughton, MA 02072 or call 781-828-4400.

STD Med, Inc.

CONTACT: Andrea Patisteas of STD Med, +1-508-728-0981


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES